Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07075471 · ClinicalTrials.gov registry record
Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib
A clinical trial of Tenosynovial Giant Cell Tumor, sponsored by Deciphera Pharmaceuticals.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT07075471 is a study of Tenosynovial Giant Cell Tumor that is actively recruiting participants, run by Deciphera Pharmaceuticals. The registered enrollment target is 100 participants, roughly in line with the 105-participant average among 8 other Tenosynovial Giant Cell Tumor trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT07075471, a study of Tenosynovial Giant Cell Tumor, is actively recruiting participants, sponsored by Deciphera Pharmaceuticals.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT. This study will collect data in an observational disease registry involving no intervention to the participants and will not influence standard medical care or impact treatment decisions for participants.
Conditions Studied
Study Locations (1)
North Carolina
- Synexus Clinical Research, US INC - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-09-03 |
| Est. Completion | 2027-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07075471
The ClinicalTrials.gov registry entry for NCT07075471 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 105-participant average among 8 other Tenosynovial Giant Cell Tumor trials with a reported enrollment target. The listed sponsor is Deciphera Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tenosynovial Giant Cell Tumor appearing as the primary indexed condition, and to 0 interventions.
NCT07075471 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT07075471 about?
NCT07075471 is a clinical study titled "Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib". The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT. This study will collect data in an observational disease registry involving no intervention to the pa...
What is the current status of trial NCT07075471?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2025-09-03. Estimated completion is 2027-09.
What conditions does trial NCT07075471 study?
This clinical trial studies the following conditions: Tenosynovial Giant Cell Tumor.
Who is sponsoring clinical trial NCT07075471?
This trial is sponsored by Deciphera Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07075471 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tenosynovial Giant Cell Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
RECRUITING · Phase 1
-
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
RECRUITING
-
Study of Vimseltinib for Tenosynovial Giant Cell Tumor
ACTIVE NOT RECRUITING · Phase 3
-
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
ACTIVE NOT RECRUITING · Phase 1
-
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.